Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.
The cash-and-stock deal, worth $886m up front, is the first major liquid biopsy acquisition since Roche bought Foundation Medicine.
A first-in-human study of the companies’ neoantigen mRNA cancer vaccine fails to rewrite these agents’ poor history.
Biogen’s aducanumab filing is keenly awaited, as are clinical data from Sanofi, Bristol Myers Squibb, Lilly and others.
Roche’s Akt inhibitor’s first pivotal result, in first-line prostate cancer, is at best a partial success and at worst an irrelevance.
Followers of Nordic Nanovector and Oxford Biomedica, among others, will pay close attention to an early focus of yesterday’s deal.
Abbvie pays handsomely to join the CD20 bispecific brawl, handing over $750m to Genmab for access to a project that trails the competition.
As Merck & Co’s Keynote-361 study fails, attention turns to Bavencio’s Asco late-breaker and the potential of Padcev.
With a $3.2bn valuation ahead of its Nasdaq float – and a market cap that is now 50% higher – Legend Biotech enters the IPO record books.